Huntington disease: new insights on the role of huntingtin cleavage

  • C. L. Wellington
  • B. R. Leavitt
  • M. R. Hayden
Conference paper


Huntington Disease (HD) results from polyglutamine expansion within the N-terminus of huntingtin. We have produced yeast artificial chromosome (YAC) transgenic mice expressing normal (YAC18) and mutant (YAC46 and YAC72) human huntingtin in a developmentally appropriate and tissue-specific manner identical to the pattern of expression of endogenous huntingtin. YAC46 and YAC72 mice show early electrophysiological abnormalities indicating neuronal cytoplasmic dysfunction prior to developing nuclear inclusions or neurodegeneration. YAC72 mice display a hyperkinetic movement disorder by 7 months of age, and have evidence for selective and specific degeneration of medium spiny neurons in the lateral striatum by 12 months of age. A key molecular feature of pathology of these YAC72 mice is cleavage of huntingtin in the cytoplasm following by translocation of the resulting huntingtin N-terminal fragments into the nucleus of striatal neurons. Increasing nuclear localization of huntingtin N-terminal fragments within medium spiny neurons of the striatum occurs concomitantly with the onset of selective neurodegeneration. Because huntingtin is a caspase substrate and truncated huntingtin fragments are toxic in vitro, inhibiting caspase cleavage of hunting tin may be of potential therapeutic benefit in HD. We show that caspase inhibitors eliminate huntingtin cleavage in cells and protects them from an apoptotic stress.


Yeast Artificial Chromosome Medium Spiny Neuron Polyglutamine Tract HN33 Cell Apoptotic Stress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andrew S.E., et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington disease. Nature Genet 4: 398–403PubMedCrossRefGoogle Scholar
  2. Becher M.W., et al (1997) Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov Disord 12: 519–530PubMedCrossRefGoogle Scholar
  3. Cooper J.K., et al (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats from nuclear and cytoplasmic aggregates in vitro. Hum Mol Genet 7:783–790PubMedCrossRefGoogle Scholar
  4. Davies S.W., et al (1997) Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537–548PubMedCrossRefGoogle Scholar
  5. DiFiglia M, et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990–1993PubMedCrossRefGoogle Scholar
  6. Duyao M, et al (1993) Trinucleotide repeat length instability and age of onset in Huntington disease. Nature Genet 4: 387–392PubMedCrossRefGoogle Scholar
  7. Ellerby L.M., et al (1999) Kennedy’s disease: caspase cleavege of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 72: 185–195PubMedCrossRefGoogle Scholar
  8. Goldberg Y.P., et al (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet 13: 442–449PubMedCrossRefGoogle Scholar
  9. Hackam A.S., et al (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 141: 1097–1105PubMedCrossRefGoogle Scholar
  10. Harper P.S. (1991) Huntington’s disease. WB Saunders, London PhiladelphiaGoogle Scholar
  11. Hayden M.R. (1981) Huntington’s chorea. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  12. Hodgson J.G., et al (1996) Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum Mol Genet 5: 1875–1885PubMedCrossRefGoogle Scholar
  13. Hodgson J.G., et al (1999) A YAC mouse model for Huntington’s disease with full-length mutant huntingtin cytoplasmic toxicity and selective striatal neurodegeneration. Neuron 23: 181–192PubMedCrossRefGoogle Scholar
  14. Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971–983CrossRefGoogle Scholar
  15. Klement I.A., et al (1998) Ataxin-1 nuclear localization and aggregation: role n polyglutamine-induced disease in SCA1 transgenic mice. Cell 95: 41–53PubMedCrossRefGoogle Scholar
  16. Leavitt B.R., Wellington C.L., Hayden M.R. (1999) Recent insights into the pathogenesis of Huntington Disease. Semin Neurol 19: 385–395PubMedCrossRefGoogle Scholar
  17. Lunkes A, Mandel J-L (1998) A cellular model that recapitulates major pathogenetic steps of Huntingtons Disease. Hum Mol Genet 7: 1355–1361PubMedCrossRefGoogle Scholar
  18. Mangiarini L, et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493–506PubMedCrossRefGoogle Scholar
  19. Martindale D, et al (1998) Length of the protein and polyglutamine tract influence localization and frequency of intracellular aggregates of huntingtin. Nature Genet 18: 150–154PubMedCrossRefGoogle Scholar
  20. Ona V.O., et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399: 263–267PubMedCrossRefGoogle Scholar
  21. Paulson H.L., et al (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333–344PubMedCrossRefGoogle Scholar
  22. Reddy P.H., et al (1998) Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genet 20: 198–202PubMedCrossRefGoogle Scholar
  23. Robitaille Y, Lopes-Cendes I, Becher M, Rouleau GA, Clark A.W. (1997) The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Path 7: 901–926CrossRefGoogle Scholar
  24. Sanchez I, et al (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22: 623–633PubMedCrossRefGoogle Scholar
  25. Saudou F, Finkbeiner S, Devys D, Greenberg M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55–66PubMedCrossRefGoogle Scholar
  26. Skinner P.J., et al (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrixassociated structures. Nature 389: 971–974PubMedCrossRefGoogle Scholar
  27. Vonsattel J.P., et al (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44: 559–577PubMedCrossRefGoogle Scholar
  28. Wellington C.L., Hayden MR (1997) Of molecular interactions mice and mechanisms: new insights into Huntington’s disease. Curr Opin Neurol 10: 291–298PubMedCrossRefGoogle Scholar
  29. Wellington C.L., et al (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158–9167PubMedCrossRefGoogle Scholar
  30. Wellington C.L., et al (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem (in press)Google Scholar

Copyright information

© Springer-Verlag Wien 2000

Authors and Affiliations

  • C. L. Wellington
    • 1
  • B. R. Leavitt
    • 1
  • M. R. Hayden
    • 1
  1. 1.Centre for Molecular Medicine and TherapeuticsVancouverCanada

Personalised recommendations